This is a revised, competitive renewal, T32 application in which we have coalesced and reconfigured two previously distinct and successful T32 programs at the Icahn School of Medicine at Mount Sinai (ISMMS), a post-doc program in Transplant Immunology [(P Heeger, former program director (PD)] and a pre-/post-doc program in Immunology (S Lira, former PD), into an expanded pre- and post-doctoral training program in Translational Immunology (P Heeger and S Lira Co-PDs). Combining the programs will a) enhance translational immunology training (including training in transplantation) through cross fertilization (e.g. exposing trainees in cancer immunology to transplant immunology, immunodeficiency and autoimmunity through a joint training venue) b) leverage common training faculty and institutional resources, as well as a revised immunology-focused, administrative infrastructure (including education, career development and evaluation processes) to enhance function and efficiency of the training experience, and c) limit overlap among training faculty. Additional rationale include 1) our success over the past 16 years in attracting and training pre- and post-doctoral MD, PhD and MD/PhD trainees into immunology research careers, 2) the continued need for improving outcomes of immune-mediated diseases 3) our desire to positively impact the education of future basic and translational investigators in immunology, and 4) the fact that our training environment and research foci are well-suited to offer diverse basic and translational immunology research opportunities for trainees. The exceptional ability of Mount Sinai's immunology community to make fundamental discoveries, to translate the results into novel and effective diagnostic and therapeutic strategies, and to incorporate pre- and post-doc training into its research mission underscores the significance of this revised training program. The overall objective of this program is to attract and train talented MD/PhD and PhD students and post-docs over 2 year periods, for successful, independent careers in immunology relevant to human disease. We have a diverse, well-funded faculty with broad interest in immunology and a strong pool of pre- and post-doc trainees that includes significant numbers of underrepresented minorities. The program is designed to provide training by individual mentors performing research in all aspects of Immunology relevant to human disease. The program is supported with strong oversight and administrative structure, significant didactic training in Immunology, scientific writing and career development, and contains newly added state of the art evaluation approaches with defined goals and benchmarks for success so as to optimize the development of independent academic researchers in the field.
This revised pre- and post-doctoral training program in Translational Immunology will attract pre-doctoral PhD and MD/PhD as well as post-doctoal MD, PhD and MD/PhD candidates into a comprehensive training environment to teach them cutting edge Immunology relevant to human disease so as move the field of translational immunology forward. The program is directly relevant to public health in that its goal is to train the next generation of leaders in Immunology and thus be able to improve outcomes of patients with cancer, autoimmune disease, allergies, immunodeficiencies, transplanted organs, among others.
|Fribourg, M; Ni, J; Nina Papavasiliou, F et al. (2018) Allospecific Memory B Cell Responses Are Dependent on Autophagy. Am J Transplant 18:102-112|
|A Verghese, Divya; Demir, Markus; Chun, Nicholas et al. (2018) T Cell Expression of C5a Receptor 2 Augments Murine Regulatory T Cell (TREG) Generation and TREG-Dependent Cardiac Allograft Survival. J Immunol 200:2186-2198|
|Chun, N; Fairchild, R L; Li, Y et al. (2017) Complement Dependence of Murine Costimulatory Blockade-Resistant Cellular Cardiac Allograft Rejection. Am J Transplant 17:2810-2819|
|Ruggenenti, Piero; Cravedi, Paolo; Chianca, Antonietta et al. (2017) Achieving remission of proteinuria in childhood CKD. Pediatr Nephrol 32:321-330|
|Crespo, Elena; Cravedi, Paolo; Martorell, Jaume et al. (2017) Posttransplant peripheral blood donor-specific interferon-? enzyme-linked immune spot assay differentiates risk of subclinical rejection and de novo donor-specific alloantibodies in kidney transplant recipients. Kidney Int 92:201-213|
|Angeletti, Andrea; Baraldi, Olga; Chiocchini, Anna Laura et al. (2017) Rituximab as First-Line Therapy in Severe Lupus Erythematosus with Neuropsychiatric and Renal Involvement: A Case-Report and Review of the Literature. J Clin Case Rep 7:|
|Petrosyan, Astgik; Da Sacco, Stefano; Tripuraneni, Nikita et al. (2017) A step towards clinical application of acellular matrix: A clue from macrophage polarization. Matrix Biol 57-58:334-346|
|Purroy, Carolina; Fairchild, Robert L; Tanaka, Toshiaki et al. (2017) Erythropoietin Receptor-Mediated Molecular Crosstalk Promotes T Cell Immunoregulation and Transplant Survival. J Am Soc Nephrol 28:2377-2392|
|Cravedi, Paolo (2017) Rituximab in Membranous Nephropathy: Not All Studies Are Created Equal. Nephron 135:46-50|
|Fribourg, Miguel; Logothetis, Diomedes E; González-Maeso, Javier et al. (2017) Elucidation of molecular kinetic schemes from macroscopic traces using system identification. PLoS Comput Biol 13:e1005376|
Showing the most recent 10 out of 38 publications